Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Results | NCT02131064 | over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02131064', 'Intervention': ['INTERVENTION 1: ', ' TCH + P', ' Participants received pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion, trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion, ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | adae7d81-bc8e-48e4-b966-27c2633eb72d | |
Single | Intervention | NCT00082810 | Throughout the duration of the primary trial, pariticpants receive tipifarnib more often than Fulvestrant. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00082810', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg + Tipifarnib 300 mg', ' Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4ee4061e-a532-459e-8d03-3055bd92419c | |
Single | Adverse Events | NCT00992225 | Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00992225', 'Intervention': ['INTERVENTION 1: ', ' LY573636-sodium', ' Dose was adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4cbb7f8f-ea60-453d-b4ab-e967944426d3 | |
Comparison | Eligibility | NCT00209092 | NCT00631852 | A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial, but not for the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00209092', 'Intervention': ['INTERVENTION 1: ', ' Arm A:Sequential Therapy', ' Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', 'I... | {'Clinical Trial ID': 'NCT00631852', 'Intervention': ['INTERVENTION 1: ', ' American Ginseng Root', ' four, 250mg tablets daily 5-14 days prior to surgery', ' American Ginseng root: four, 250mg tablets daily 5-14 days prior to surgery'], 'Eligibility': ['Inclusion Criteria:', ' Patients with cytologically confirmed... | 47f11df7-6c82-4c50-9249-5085313a5064 |
Single | Adverse Events | NCT01961544 | the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1. | Entailment | [
0,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01961544', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3114ff0f-184c-48ba-b33d-631505cffeef | |
Single | Results | NCT02595372 | 27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02595372', 'Intervention': ['INTERVENTION 1: ', ' High Dose Omeprazole Treatment', ' Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.'], 'Eligibility': ['Inclusion Criteria', ' Newly diagnosed triple negative br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | edf31a43-a774-4f2a-8a02-89b84de941bb | |
Comparison | Adverse Events | NCT01596751 | NCT00193050 | There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts. | Contradiction | [
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01596751', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib: Eribulin in Combination With PLX3397', ' Phase Ib:', ' 21 day treatment cycle: PLX3397 100-200 mg gelcaps, by mouth daily & Eribulin 1.4 mg/m2 intravenously, day 1 and 8', ' Cohort 1: 600 mg/day', ' Cohort 2: 800 mg/day', ' Coho... | {'Clinical Trial ID': 'NCT00193050', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then ha... | ffdc4c5b-a091-4fa6-b2c1-49a131d7d109 |
Single | Intervention | NCT00632489 | the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00632489', 'Intervention': ['INTERVENTION 1: ', ' LBH589 With Capecitabine', ' MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5 | |
Comparison | Intervention | NCT03456427 | NCT02685566 | There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03456427', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants: Patient Assisted Compression', ' All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Comp... | {'Clinical Trial ID': 'NCT02685566', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.', ' This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in can... | 5a076708-c8d4-4341-9c1d-3ee762f57be5 |
Comparison | Results | NCT02038010 | NCT00764322 | Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02038010', 'Intervention': ['INTERVENTION 1: ', ' Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1)', ' Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of dis... | {'Clinical Trial ID': 'NCT00764322', 'Intervention': ['INTERVENTION 1: ', ' Ultra-rapid Metabolizers', ' Those with the highest transformation of the CYP2D6 genotype to allelic activity', 'INTERVENTION 2: ', ' Extensive Metabolizers', ' Those with the most normal transformation of the CYP2D6 genotype to allelic act... | 98a946b0-2be1-474c-b373-043f329ba261 |
Comparison | Eligibility | NCT00721409 | NCT02413320 | Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00721409', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 (Palbociclib + Letrozole)', ' In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.... | {'Clinical Trial ID': 'NCT02413320', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin + Paclitaxel Then Doxorubicin + Cyclophosphamide', ' Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (60... | b82e6861-3908-43e9-8e54-cf60c7d96a4e |
Comparison | Adverse Events | NCT02445586 | NCT02115984 | More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT02445586', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Docetaxel', ' Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, wh... | {'Clinical Trial ID': 'NCT02115984', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy & Panagen', ' Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.', ' Panagen 5 mg tablet by mouth every 2-3 h (six times a ... | b8e5baf7-ddc5-407f-84d3-4c93224477cd |
Single | Intervention | NCT01277757 | the primary trial is not testing a novel Physiotherapy or chemotherapy intervention. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01277757', 'Intervention': ['INTERVENTION 1: ', ' Akt Inhibitor MK-2206', ' Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg, courses repeat every 28 days.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79c34b71-a90f-4ddb-9aee-5f61f71f0846 | |
Single | Eligibility | NCT02995980 | A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial. | Entailment | [
0,
3,
4
] | [] | {'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e1f6d1b3-92eb-4ad8-8c00-e44b58650e62 | |
Comparison | Intervention | NCT00438659 | NCT01271725 | the primary trial and the secondary trial have a topical intervention, to be applied to the breast or face. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00438659', 'Intervention': ['INTERVENTION 1: ', ' Mometasone', ' Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.', 'INTERVENTION 2: ', ' Placebo', ' Patients apply 2.5 mL of an identical-appear... | {'Clinical Trial ID': 'NCT01271725', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Monotherapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Pati... | 02d5fe7a-60e2-422f-98c0-92461b8fa13f |
Comparison | Eligibility | NCT00996632 | NCT01644890 | Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial. | Contradiction | [
0,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00996632', 'Intervention': ['INTERVENTION 1: ', ' Ultrasonic', ' Patients were operated using an ultrasonic knife (Ultracision Ethicon TM)', 'INTERVENTION 2: ', ' Conventional', ' Patients were operated by a conventional diatherm knife'], 'Eligibility': ['Inclusion Criteria:', ' Operable ... | {'Clinical Trial ID': 'NCT01644890', 'Intervention': ['INTERVENTION 1: ', ' NK105', ' received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', 'INTERVENTION 2: ', ' Paclitaxel', ' received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' Written inf... | 869e413e-01c5-4a9e-8a4a-b6079f7ae300 |
Single | Eligibility | NCT01142661 | the primary trial accepts patients with grade 3 neuropathy. | Contradiction | [
17,
19
] | [] | {'Clinical Trial ID': 'NCT01142661', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', 'Eribulin Mesylate : Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.'], 'Eligibility': ['Inclusion Crite... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c0b528ef-ae9f-4c01-8915-b47856f07c95 | |
Single | Results | NCT01743560 | By week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT01743560', 'Intervention': ['INTERVENTION 1: ', ' Everolimus and Exemestane', ' Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.'], 'Eligibility': [... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e | |
Single | Eligibility | NCT01011946 | All patients in the primary trial must have a bilateral breast MRI prior to study entry. | Entailment | [
2,
7
] | [] | {'Clinical Trial ID': 'NCT01011946', 'Intervention': ['INTERVENTION 1: ', ' Positron Emission Mammography', ' Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ul... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | da15fae6-7fa1-4fe0-b61c-e043df3e9e74 | |
Single | Eligibility | NCT02455453 | Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial. | Entailment | [
0,
10
] | [] | {'Clinical Trial ID': 'NCT02455453', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FFNP-PET/CT Scan', ' (2) 18F-FFNP-PET/CT scans', ' First one prior to estradiol challenge test', ' Second one immediately following one day of estradiol challenge test', ' (1) FDG-PET/CT scan at screening', ' The estradiol chal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8ce665b5-20fb-44a3-b3c9-25493e8dd7ff | |
Single | Results | NCT02555657 | The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02555657', 'Intervention': ['INTERVENTION 1: ', ' Pembrolizumab', ' Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years).', 'INTERVENTION 2: ', ' Chemotherapy', " Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as s... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 01236718-14da-450c-8051-0207d31743a5 | |
Single | Eligibility | NCT03719677 | Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2. | Entailment | [
7
] | [] | {'Clinical Trial ID': 'NCT03719677', 'Intervention': ['INTERVENTION 1: ', ' Habit Development Intervention', ' Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, th... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3419af1a-7923-419d-a673-2de96d41eabb | |
Comparison | Eligibility | NCT01966471 | NCT00981812 | A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial. | Entailment | [
0,
4,
5
] | [
5,
12
] | {'Clinical Trial ID': 'NCT01966471', 'Intervention': ['INTERVENTION 1: ', ' Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane', ' Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) c... | {'Clinical Trial ID': 'NCT00981812', 'Intervention': ['INTERVENTION 1: ', ' Lesions Visualized Using Positron Emission Mammography (PEM)', ' Total lesions visualized using positron emission mammography.'], 'Eligibility': ['Inclusion Criteria:', ' female', ' subject is 25-100 years of age', ' subjects has at least ... | 2048912d-9e9f-4cbc-89cc-19020f20a976 |
Comparison | Intervention | NCT00245219 | NCT00038103 | the primary trial and the secondary trial both have control groups. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00245219', 'Intervention': ['INTERVENTION 1: ', ' Health Tracking (Control)', ' Participants assigned to the health-tracking condition received usual care and did not attend any meetings.', 'INTERVENTION 2: ', ' Peer Support', ' The peer support group meetings focused on fostering purpose ... | {'Clinical Trial ID': 'NCT00038103', 'Intervention': ['INTERVENTION 1: ', ' Exemestane (Exemestane Alone)', ' oral dose exemestane taken with food (25 mg tablet once daily)', 'INTERVENTION 2: ', ' Combination (Exemestane + Celecoxib)', ' oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxi... | f5907902-d4d1-4d73-a196-7fbe0dcb44ad |
Comparison | Adverse Events | NCT01463007 | NCT00965523 | A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT01463007', 'Intervention': ['INTERVENTION 1: ', ' Radiation', ' AccuBoost APBI- 34.0 Gy in 10fx', ' Accelerated partial breast irradiation: Accuboost APBI 34.0 Gy in 10 fractions', 'INTERVENTION 2: ', ' Extended to 5 Years of Follow Up-Rhode Island Hospital Only', ' Follow up has been ext... | {'Clinical Trial ID': 'NCT00965523', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate 1.4 mg/m^2 intravenous infusion given over 2 to 5 minutes on Day 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion criteria:', ' Female patients with histologically or cytologically confirmed breast... | 93a8e018-ac25-48b2-81d2-fd5b01be8f37 |
Single | Eligibility | NCT00464646 | Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial. | Entailment | [
0,
15,
16,
17,
18,
19,
10
] | [] | {'Clinical Trial ID': 'NCT00464646', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', 'INTERVENTION 2: ', ' Cohort B', ' Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer'], 'Eligibili... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d72c45e5-6654-4afe-91a0-1f47b0c13dc0 | |
Single | Adverse Events | NCT01033032 | The only adverse event recorded in the primary trial was one single case of spinal fracture. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' F... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e68b5690-11fd-4567-8dcc-dec91d1e4bb8 | |
Comparison | Adverse Events | NCT01931163 | NCT00274469 | Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01931163', 'Intervention': ['INTERVENTION 1: ', ' Everolimus Plus Cisplatin', ' Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age.', ' Cl... | {'Clinical Trial ID': 'NCT00274469', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', 'Fulvestrant 500 mg', 'INTERVENTION 2: ', ' Anastrozole 1 mg', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed hormone receptor positive advanced breast cancer, postmenopausal women', 'Exclusion C... | e1417a26-2f40-4dd6-b598-e66e57312595 |
Single | Adverse Events | NCT00365365 | the primary trial only recorded one type of acute adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00365365', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1 (AC->T + Bevacizumab)', ' HER2-negative participants administered', ' doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by', ' docetaxel (T) + bevacizumab for 4 cycles followed by', ' bevacizumab maintenan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6ee89773-958b-4eb9-bc67-18fa98a70c2d | |
Single | Adverse Events | NCT00063570 | None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00063570', 'Intervention': ['INTERVENTION 1: ', ' Bi-Weekly Schedule', ' Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.', ' Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.', 'INTERVENTION 2: ', ' 21-Day Schedule', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4d776c28-8ed1-4f3f-9837-0821029d3775 | |
Comparison | Intervention | NCT00611624 | NCT00600340 | the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00611624', 'Intervention': ['INTERVENTION 1: ', ' Five Days of Mammosite Therapy', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' The patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines.', ' Patient m... | {'Clinical Trial ID': 'NCT00600340', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab Plus Paclitaxel', ' Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks', 'INTERVENTION 2: ', ' Bevacizumab Plus Capecitabine', ' Bevacizumab 15 mg/kg i.v.,... | 50e54a67-9cfb-4259-b810-2e9bc0b09b4c |
Comparison | Adverse Events | NCT00688740 | NCT00191815 | The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00688740', 'Intervention': ['INTERVENTION 1: ', ' TAC (Docetaxel)', ' docetaxel in combination with doxorubicin and cyclophosphamide', 'INTERVENTION 2: ', ' FAC (5-fluorouracil)', ' 5-fluorouracil in combination with doxorubicin and cyclophosphamide'], 'Eligibility': ['Inclusion Criteria:'... | {'Clinical Trial ID': 'NCT00191815', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Cisplatin', ' Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).'], 'Eligibility': ... | 9f23f617-b8ec-4665-ad0b-9a9bc8b19691 |
Comparison | Intervention | NCT01490892 | NCT02364388 | The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01490892', 'Intervention': ['INTERVENTION 1: ', ' 3D HI and SHI of UCA', ' Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 m... | {'Clinical Trial ID': 'NCT02364388', 'Intervention': ['INTERVENTION 1: ', ' MAESTRO', 'Baseline'], 'Eligibility': ['Inclusion Criteria', ' Female', ' 18 years of age or older', ' Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-R... | b76c9c21-64f7-487b-bf08-e232a9da0174 |
Comparison | Eligibility | NCT03136367 | NCT00129935 | Only patients who identify as female are eligible for the secondary trial and the primary trial. | Contradiction | [
0,
1,
6,
7
] | [
18,
38
] | {'Clinical Trial ID': 'NCT03136367', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Option Grid', ' Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.', ' Op... | {'Clinical Trial ID': 'NCT00129935', 'Intervention': ['INTERVENTION 1: ', ' Arm A: EC-T', ' Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycle... | 66aaca41-f5f9-4ed4-b165-9510b7c64456 |
Single | Adverse Events | NCT00206427 | A patient in the primary trial had a fungal infection of the mouth. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00206427', 'Intervention': ['INTERVENTION 1: ', ' GW572016 1500mg', ' patients received GW572016 1500mg daily'], 'Eligibility': ['Inclusion Criteria:', ' All patients must be female.', ' Signed informed consent.', ' Locally advanced breast cancers or primary breast cancers with concomitan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 611317e3-83f9-4e8d-9a9d-3dcda62fb6cb | |
Single | Adverse Events | NCT01216176 | Urosepsis was the most common adverse event in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT01216176', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 - Cohort A', ' Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer', ' Anastrozole',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d6b09c0f-979c-4151-87f9-830b964e275d | |
Comparison | Results | NCT01570036 | NCT00021255 | the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years. | Entailment | [
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01570036', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + NeuVax Vaccine', ' Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of st... | {'Clinical Trial ID': 'NCT00021255', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)', ' Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m... | 92da8d30-a7e9-4fb4-95e4-484b53279ad7 |
Single | Eligibility | NCT02165605 | A 56 year old patient with a masectomy would not be eligible for the primary trial, due to her age. | Contradiction | [
0,
1,
3
] | [] | {'Clinical Trial ID': 'NCT02165605', 'Intervention': ['INTERVENTION 1: ', ' HylaCare', ' Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 762c3b23-547a-40cb-86c9-767294f4a142 | |
Single | Adverse Events | NCT01111825 | There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [] | {'Clinical Trial ID': 'NCT01111825', 'Intervention': ['INTERVENTION 1: ', ' Phase 2 Triple -ve', ' Phase 2, Triple - Negative cohort', 'INTERVENTION 2: ', ' Phase 2 HER2+', ' Phase 2, HER2 - Amplified (HER2-Positive) cohort'], 'Eligibility': ['Inclusion Criteria:', ' Phase I HER2-amplified Cohort', ' HER2 overexp... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 95a509d6-2990-49ac-b36c-aedf842f17ee | |
Single | Adverse Events | NCT00258960 | One patient in the primary trial experienced a grade 4 adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00258960', 'Intervention': ['INTERVENTION 1: ', ' Caelyx,Cyclophosphamide,Trastuzumab', ' Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6 | |
Comparison | Adverse Events | NCT00066573 | NCT01091454 | There was 1 case of night blindness in the primary trial, and 0 in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00066573', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Patients receive oral exemestane (25 mg) once daily for 5 years.', ' exemestane: Given orally', 'INTERVENTION 2: ', ' Anastrozole', ' Patients receive oral anastrozole (1 mg) once daily for 5 years.', ' anastrozole: Given o... | {'Clinical Trial ID': 'NCT01091454', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cisplatin and Brostallicin)', ' Patients receive 50 mg/m^2 cisplatin IV over 2 hours on day 1 and 10 mg/m^2 brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | 19c2c2d7-4c33-4842-9ed4-02cfae663ce2 |
Comparison | Intervention | NCT01818063 | NCT00559507 | In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01818063', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Paclitaxel, Carboplatin)', ' Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxici... | {'Clinical Trial ID': 'NCT00559507', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy)', ' Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically... | 1fdaafdc-766b-488e-9cc4-cbcad74ade97 |
Single | Eligibility | NCT02040857 | All genders are eligible for the primary trial. | Entailment | [
2
] | [] | {'Clinical Trial ID': 'NCT02040857', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib With Adjuvant Endocrine Therapy', ' Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd'], 'Eligibility': ['Inclusion Criteria:', ' Pa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e591059-5a3b-4a69-84c5-59d9604394a8 | |
Single | Adverse Events | NCT00866905 | Less than 1% of patients in the primary trial became depressed. | Entailment | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT00866905', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Cyclophosphamide', ' Systemic Therapy followed by surgery and possible radiation therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years.', ' Histologically confirmed invasive adenocarcinoma of the brea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94a54cdf-4c1c-4994-929a-ced7a33f2b43 | |
Single | Eligibility | NCT00562718 | Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion. | Entailment | [
6
] | [] | {'Clinical Trial ID': 'NCT00562718', 'Intervention': ['INTERVENTION 1: ', ' Surgery and Chemotherapy', ' Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.', ' capecitabine', ' adjuvant ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b217583e-2dbb-4951-8f73-cac08e365a7a | |
Single | Eligibility | NCT00304096 | A minimum bodyweight of 50kg is required to participate in the primary trial. | Entailment | [
14
] | [] | {'Clinical Trial ID': 'NCT00304096', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Received Hormonal Therapy', ' Participants received hormonal therapy', 'INTERVENTION 2: ', ' Stratum 2: Had Not Received Hormonal Therapy', ' Participants had not received hormonal therapy'], 'Eligibility': ['DISEASE CHARACTERIST... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 42086f11-1fb1-4041-8d1e-e150d4cc09ea | |
Single | Intervention | NCT00916578 | the primary trial is testing a combination of chemotherapy and radiotherapy. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00916578', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Institution, Open Label, Phase II', ' Patients will received 825 mg/m2 bid of capecitabine. One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy. Capecitabine will be administered when pati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0d75c493-58ce-4a45-8823-a9a1126751b3 | |
Single | Results | NCT00303108 | Cohort 2 of the primary trial produced marginally better results than cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00303108', 'Intervention': ['INTERVENTION 1: ', ' D+C and Taxane Naive', ' Doxil, Carboplatin and Taxane naive', 'INTERVENTION 2: ', ' D+C and Taxane Pretreated', ' Doxil, Carboplatin and Taxane pretreated'], 'Eligibility': ['Inclusion Criteria:', ' Has metastatic breast cancer with docum... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d0d4e184-0764-4c28-9af7-4535c7ed1aad | |
Single | Eligibility | NCT02413320 | Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for the primary trial. | Contradiction | [
0,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02413320', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin + Paclitaxel Then Doxorubicin + Cyclophosphamide', ' Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (60... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e45886af-1edd-4987-a280-2609a86fd3dd | |
Single | Intervention | NCT03374995 | Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT03374995', 'Intervention': ['INTERVENTION 1: ', ' Group I (Topical Keratin)', ' Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).', ' Quality-of-Life Assessment: Ancillary studies', ' Topical Keratin: Given topically', 'IN... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c207ff16-b7d0-49e4-9177-0597044f3008 | |
Single | Results | NCT00550771 | 16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00550771', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD) Based Regimen', ' PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 35234f08-cf01-478f-b739-600b5a6ea3d9 | |
Single | Eligibility | NCT01805089 | Patients with Lactiferous duct carcinomas are eligible for the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01805089', 'Intervention': ['INTERVENTION 1: ', ' Melatonin', ' Taken orally, once per day, at/around 9:00pm', 'Melatonin', 'INTERVENTION 2: ', ' Placebo', ' Taken orally, once per day, at/around 9:00pm', 'Placebo'], 'Eligibility': ['Inclusion Criteria:', ' History of ductal carcinoma in ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 87adb323-6f56-4e1a-a04d-8437ac571eab | |
Comparison | Intervention | NCT00194779 | NCT04080297 | There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00194779', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' meth... | {'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.']... | 94410f2c-9c1c-4130-b479-738e343ba9f7 |
Comparison | Eligibility | NCT00671918 | NCT00571987 | Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial. | Entailment | [
0,
12
] | [
0,
9
] | {'Clinical Trial ID': 'NCT00671918', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | {'Clinical Trial ID': 'NCT00571987', 'Intervention': ['INTERVENTION 1: ', ' Margin Status', ' AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated... | b811e872-90ef-4649-9c8d-f5488f316ccc |
Comparison | Intervention | NCT02835625 | NCT00486525 | the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02835625', 'Intervention': ['INTERVENTION 1: ', ' Digital Breast Tomosynthesis', ' Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for furth... | {'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ... | f66f4c30-2d39-4e29-876a-487bca9a8ccf |
Single | Results | NCT00452673 | 7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00452673', 'Intervention': ['INTERVENTION 1: ', ' 50 mg Dasatinib + 825 mg/m^2Capecitabine', ' Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID. Participants were treated at each dose level (DL) for minim... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6 | |
Single | Adverse Events | NCT00086957 | All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00086957', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Docetaxel 75 mg/m^2', ' Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 wee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 011991a5-724d-4b95-b9ab-9e1371d77368 | |
Comparison | Adverse Events | NCT02896855 | NCT00171314 | the secondary trial recorded more total occurences of cardiac adverse events than the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT02896855', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Placebo + Trastuzumab + Docetaxel', ' Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg... | {'Clinical Trial ID': 'NCT00171314', 'Intervention': ['INTERVENTION 1: ', ' Upfront Zoledronic Acid', ' Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ', ' De... | 8421197a-3a35-4738-b1c8-83cce0ac4115 |
Comparison | Adverse Events | NCT03176238 | NCT01498458 | Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03176238', 'Intervention': ['INTERVENTION 1: ', ' Asian Everolimus + Exemestane', ' Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily. Participants in Asian countries: Indonesia, India, Vietnam, Turkey, South Korea, Thailand, Malaysia, Taiwan or Jordan.... | {'Clinical Trial ID': 'NCT01498458', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib Plus Capecitabine', ' A maximal tolerated dose (MTD) could not be established. The study was stopped after 8 patients.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent for all study procedures according to local... | d09091f1-3fc5-498b-8c59-4678590c8464 |
Single | Eligibility | NCT00821886 | Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial. | Entailment | [
20,
33
] | [] | {'Clinical Trial ID': 'NCT00821886', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Trastuzumab/Carboplatin', ' Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 203a2e22-cae9-4bfe-b82d-6dc665a66ce6 | |
Single | Adverse Events | NCT02574455 | More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT02574455', 'Intervention': ['INTERVENTION 1: ', ' Sacituzumab Govitecan', ' Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. In... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f4909215-5b14-42d9-bda4-4d112cf2a108 | |
Comparison | Adverse Events | NCT00093808 | NCT00394082 | the primary trial and the secondary trial reported the same number of dehydrated patients during the studies. | Entailment | [
11
] | [
11
] | {'Clinical Trial ID': 'NCT00093808', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Vinorelbine + Trastuzumab', ' Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 o... | {'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If... | 9c27202c-7090-4be5-840e-351992aeb81c |
Comparison | Adverse Events | NCT00528567 | NCT01196052 | The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial. | Entailment | [
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00528567', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab and Chemotherapy', ' Participants randomized to receive bevacizumab and chemotherapy', 'INTERVENTION 2: ', ' Chemotherapy', ' Participants randomized to receive chemotherapy alone'], 'Eligibility': ['Inclusion Criteria:', ' adu... | {'Clinical Trial ID': 'NCT01196052', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Adult patients 18 years of age.', ' ... | fc7d8ffd-9896-4806-a095-d435cde83c88 |
Comparison | Eligibility | NCT00876395 | NCT02287675 | Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial. | Contradiction | [
9,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00876395', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Paclitaxel + Trastuzumab', ' Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22', 'INTERVENTION 2: ', ' Placebo + Paclitaxel + Trastuzumab', '... | {'Clinical Trial ID': 'NCT02287675', 'Intervention': ['INTERVENTION 1: ', ' Lymphoseek', ' Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or... | 23116aca-0064-4426-b147-7af688a82443 |
Comparison | Eligibility | NCT00005879 | NCT01217385 | The only criterias for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and british. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT00005879', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo', ' Placebo: matched tablet dialy', 'INTERVENTION 2: ', ' Arzoxifene', ' LY353381, 20 mg daily', ' arzoxifene: one tablet daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Current random fine needle breast aspira... | {'Clinical Trial ID': 'NCT01217385', 'Intervention': ['INTERVENTION 1: ', ' Diffuse Optical Spectroscopy Imaging (DOSI', ' Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.', ' DOSI: Bedside DOSI images of the tissu... | 7dd79595-4bdf-48e6-af94-fe39aa2e5fd4 |
Single | Eligibility | NCT00033514 | Mark has HER2 positive breast cancer, he is eligible for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00033514', 'Intervention': ['INTERVENTION 1: ', ' Treatment Phase 1 Plus Phase 2', ' trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.', ' erlotinib hydrochloride: 150 mg daily.'], 'Eligibility': ['Inclusion Criteria:', ' Women aged > 18 years', ' Histologically documents metastatic breast ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 98850daf-738c-4005-b476-8c5479ad3b79 | |
Single | Intervention | NCT00916578 | the primary trial is testing a combination of capecitabine once daily with radiotherapy. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00916578', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Institution, Open Label, Phase II', ' Patients will received 825 mg/m2 bid of capecitabine. One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy. Capecitabine will be administered when pati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fd8ddc92-4625-4392-b7ef-0ea218e2eb1c | |
Single | Intervention | NCT00425854 | Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00425854', 'Intervention': ['INTERVENTION 1: ', ' Cohort B', ' Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd'], 'Eligibility': ['Inclusion criteria:', 'Inclusion Criteria:', ' Female patients age 18 years or older', ' Histolog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a4ed4cc0-9444-4a5d-863c-578fd42b8794 | |
Comparison | Eligibility | NCT01313039 | NCT01031446 | Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions. | Entailment | [
9
] | [
19
] | {'Clinical Trial ID': 'NCT01313039', 'Intervention': ['INTERVENTION 1: ', ' Single Arm', ' AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15'], 'Eligibility': ['Inclusion Criteria:', ' Female breast cancer patient > 18 years.', ' Patients must have biopsy-proven clinical Stage Ic-III inv... | {'Clinical Trial ID': 'NCT01031446', 'Intervention': ['INTERVENTION 1: ', ' RAD001 and Cisplatin and Paclitazel', ' Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks'], 'Eligibility': ['DISEASE... | a4dcb9b6-7b6f-4467-a159-d6e770f6762f |
Single | Intervention | NCT00291694 | the primary trial does not specificy the route of administration of its intervention. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00291694', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Randomized to receive celecoxib daily for 12 months', 'INTERVENTION 2: ', ' Placebo', ' Randomized to receive placebo daily for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' women who have a high risk of breast cancer... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | be1c82e6-200d-4bef-b723-c78655fa40e5 | |
Single | Results | NCT02447328 | In the primary trial 11.1% of patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients had Unexpected adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT02447328', 'Intervention': ['INTERVENTION 1: ', ' Single Arm', ' fulvestrant (Faslodex®)'], 'Eligibility': ['Inclusion Criteria:', ' Post menopausal status women', ' Outpatient or inpatient with locally advanced or metastatic breast cancer who have failed with prior anti-estrogen therapy.'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 790047b1-43e3-486e-b41c-eaa89026eae7 | |
Single | Adverse Events | NCT00875979 | None of the 3 patients in cohort 1 of the primary trial experienced any adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00875979', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg', ' Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fc8ed290-e2b3-4eea-a837-d369dcd9b5da | |
Comparison | Adverse Events | NCT00559845 | NCT00426556 | In total there were more adverse events in the secondary trial than in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
14,
15
] | {'Clinical Trial ID': 'NCT00559845', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.', ' FEC: 5-Fluorouracil 600 mg/m^2 i.v. bolus over 15 min; epirubicin 90 mg/m^2 i.v. infusion over 1 hour; cyclophosphamide 600 ... | {'Clinical Trial ID': 'NCT00426556', 'Intervention': ['INTERVENTION 1: ', ' Phase I - RAD001 5mg + PT, Daily', ' Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', 'INTERVENTION 2: ', ' Phase I - RAD001 10mg + PT, Daily', ' Daily dosing schedule of Everolimus 1... | 207b0895-91de-4238-8d50-e2b8b7420fb0 |
Single | Eligibility | NCT00317720 | Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00317720', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + RAD001', ' Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. RAD001 10 mg PO (by mouth) daily.'], 'Eligibility': ['Inclusion Criteria:', ' History of biopsy-proven HER-2-overexpressing... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1340769c-b55c-480c-a4c4-130034e128ce | |
Single | Eligibility | NCT02694029 | Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT02694029', 'Intervention': ['INTERVENTION 1: ', ' Radiation With ABC', ' Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH', ' Active Breathing Coordinator (ABC): The ABC system has a digital spirometer that records... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a4d6e27f-737b-4597-86e1-79b3f064cbee | |
Comparison | Adverse Events | NCT00887575 | NCT01610284 | Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00887575', 'Intervention': ['INTERVENTION 1: ', ' Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years', ' Histologically confirmed invasive ER-... | {'Clinical Trial ID': 'NCT01610284', 'Intervention': ['INTERVENTION 1: ', ' BKM120 100mg + Fulvestrant', ' BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.', 'INTERVENTION 2: ', ' Placebo + Fulvestrant', ' BKM120 matching placebo daily and fulvestrant given until progre... | 3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43 |
Single | Eligibility | NCT02429427 | Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial | Contradiction | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT02429427', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.', ' Celecoxib: Patients will receive 400mg of Celecoxib o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 030eded8-6513-4028-b1fe-fefd6dd388ad | |
Single | Eligibility | NCT00054275 | A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial. | Contradiction | [
33,
35
] | [] | {'Clinical Trial ID': 'NCT00054275', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and OSI-774', ' docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage IV or recurrent adenocarcinoma of the breast', ' Measur... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 412d3ee2-bbfb-4e24-b159-684ae144e742 | |
Single | Eligibility | NCT00768222 | Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial due to her age. | Contradiction | [
0,
1,
4,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00768222', 'Intervention': ['INTERVENTION 1: ', ' Chinese Silk Suture', ' Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', 'INTERVENTION 2: ', ' VICRYL* Plus Suture',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d1d77877-9c85-41c8-9eca-6fd75b254a15 | |
Single | Eligibility | NCT02279108 | Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT02279108', 'Intervention': ['INTERVENTION 1: ', ' Double Detection Indocyanine + Isotope', ' intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery', ' indocyanine green: One injection, 2.5 milligrams per patient, intradermal use', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c32d1b74-07ab-4afb-9db6-878e20727661 | |
Single | Eligibility | NCT03045653 | Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial. | Contradiction | [
4,
6
] | [] | {'Clinical Trial ID': 'NCT03045653', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' receiving a treatment of tamoxifen 100 mg/d'], 'Eligibility': ['Inclusion Criteria:', ' - Female 18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confir... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ba0c0dc6-826b-426f-8738-eec23e47f6b0 | |
Comparison | Adverse Events | NCT01301729 | NCT02129556 | Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01301729', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams p... | {'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing... | 77982c81-d147-48d9-909c-18b9a98224e9 |
Comparison | Results | NCT00687440 | NCT01307891 | Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00687440', 'Intervention': ['INTERVENTION 1: ', ' Caelyx, Docetaxel, Trastuzumab', ' Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of c... | {'Clinical Trial ID': 'NCT01307891', 'Intervention': ['INTERVENTION 1: ', ' Abraxane + Tigatuzumab', ' Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every oth... | 7f1af51d-e22b-4285-aea4-3dc80c3ab2ec |
Single | Eligibility | NCT02165605 | A 56 year old patient with a masectomy would not be eligible for the primary trial | Entailment | [
0,
1,
3
] | [] | {'Clinical Trial ID': 'NCT02165605', 'Intervention': ['INTERVENTION 1: ', ' HylaCare', ' Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e03f6f1-0d4f-4ebf-8781-20918d70d78f | |
Single | Eligibility | NCT00482391 | Patients with No QT prolongation are excluded from the primary trial. | Contradiction | [
29
] | [] | {'Clinical Trial ID': 'NCT00482391', 'Intervention': ['INTERVENTION 1: ', ' AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB', " The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 57e74ef2-f170-47bd-a908-2a7b3cec150d | |
Single | Eligibility | NCT01805089 | pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial. | Contradiction | [
0,
1,
3
] | [] | {'Clinical Trial ID': 'NCT01805089', 'Intervention': ['INTERVENTION 1: ', ' Melatonin', ' Taken orally, once per day, at/around 9:00pm', 'Melatonin', 'INTERVENTION 2: ', ' Placebo', ' Taken orally, once per day, at/around 9:00pm', 'Placebo'], 'Eligibility': ['Inclusion Criteria:', ' History of ductal carcinoma in ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b5957a75-140f-445b-99dc-199b8182b8ed | |
Single | Intervention | NCT00486525 | The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 142cc983-b0cc-4f9f-b3ef-4eb57e2a317b | |
Single | Results | NCT03252431 | patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT03252431', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.', ' F-627: single dose pre-filled syringe', 'INTERVENTION 2: ', ' Neulasta', ' 6 mg fixed dose Neulasta®, administered on Day 2 o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f57350c2-ac90-47ea-92b4-d903509bf07a | |
Single | Eligibility | NCT00167414 | Patients do not need to have a known hormone receptor status to participate in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionate... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 77c61307-567d-4ac2-a7f7-85feffd30473 | |
Single | Results | NCT00764322 | The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00764322', 'Intervention': ['INTERVENTION 1: ', ' Ultra-rapid Metabolizers', ' Those with the highest transformation of the CYP2D6 genotype to allelic activity', 'INTERVENTION 2: ', ' Extensive Metabolizers', ' Those with the most normal transformation of the CYP2D6 genotype to allelic act... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 35dd977f-53d8-4400-b5cb-34caaa938e78 | |
Single | Results | NCT00444535 | Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00444535', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib + Bevacizumab', ' Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)'], 'Eligibility': ['Inclusion criteria:', ' Females that are at least 18 years of age.', ' Women of childb... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 54554da5-e67f-4da5-819b-a85b7bc5d52c | |
Single | Intervention | NCT00343863 | On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00343863', 'Intervention': ['INTERVENTION 1: ', ' Dexamethasone + Ondansetron IV', ' All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.', ' Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubic... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 592edd64-7841-4c19-ba75-583066308137 | |
Single | Eligibility | NCT00228943 | Clinically depressed patients are not able to participate in the primary trial. | Entailment | [
8,
9
] | [] | {'Clinical Trial ID': 'NCT00228943', 'Intervention': ['INTERVENTION 1: ', ' Full Strength Acute Tryptophan Depletion', '[Not Specified]', 'INTERVENTION 2: ', ' Half-Strength Tryptophan Depletion - Control', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' At least 18 years of age', ' Willing and able to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a1d207c8-2d57-4c49-89fa-60ceacf65829 | |
Comparison | Adverse Events | NCT00093808 | NCT00394082 | the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies. | Contradiction | [
11
] | [
11
] | {'Clinical Trial ID': 'NCT00093808', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Vinorelbine + Trastuzumab', ' Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 o... | {'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If... | 4a8f0562-355b-4a68-8790-c283d93ce766 |
Comparison | Adverse Events | NCT02491892 | NCT00887575 | Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial. | Entailment | [
0,
5,
6
] | [
0,
7,
8
] | {'Clinical Trial ID': 'NCT02491892', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab 420 mg', ' Participants received a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.', 'INTERVENTI... | {'Clinical Trial ID': 'NCT00887575', 'Intervention': ['INTERVENTION 1: ', ' Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years', ' Histologically confirmed invasive ER-... | 04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4 |
Single | Eligibility | NCT02878057 | Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial. | Entailment | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT02878057', 'Intervention': ['INTERVENTION 1: ', ' Advanced Breast Cancer', ' Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolera... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3cd353ed-af0d-4356-8f45-efc1e91a2a0d | |
Comparison | Eligibility | NCT00580333 | NCT00934856 | Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial. | Entailment | [
8,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT00580333', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin/Avastin', ' Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preopera... | {'Clinical Trial ID': 'NCT00934856', 'Intervention': ['INTERVENTION 1: ', ' MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)', ' Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/... | b8473ae8-11c9-4578-aab8-ee96e6287715 |
Comparison | Adverse Events | NCT00246090 | NCT00266799 | Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial. | Entailment | [
0,
1
] | [
15,
16
] | {'Clinical Trial ID': 'NCT00246090', 'Intervention': ['INTERVENTION 1: ', ' E7389 1.4 mg/m^2', ' E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast.... | {'Clinical Trial ID': 'NCT00266799', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD)', ' PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', 'INTERVENTION 2: ', ' Capecitabine', ' Capecitabine 1250 mg/m^2, i... | 4243dc45-5a64-486d-ae2a-11448db00dcf |
Comparison | Results | NCT00073528 | NCT00191152 | cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00073528', 'Intervention': ['INTERVENTION 1: ', ' Placebo + Letrozole 2.5 mg', ' Participants received 6 tablets of placebo, identical in appearance to lapatinib tablets, orally daily (approximately at the same time each day), either 1 hour (or more) before breakfast or 1 hour (or more) afte... | {'Clinical Trial ID': 'NCT00191152', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine Plus Docetaxel', ' gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.', ' Treatment continues until progression of disease at w... | fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5 |
Comparison | Intervention | NCT00902330 | NCT00952731 | Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00902330', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Cranial Microcurrent Electrical Stimulation [CES])', ' Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is pr... | {'Clinical Trial ID': 'NCT00952731', 'Intervention': ['INTERVENTION 1: ', ' Treatment Gel + Oral Placebo', ' 4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.', ' oral placebo: Oral placebo taken daily for 4-10 weeks.', ' afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 w... | f616e3d8-6c1a-4b99-ac79-ea87895e37b7 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.